First‑in‑class SK ion channel inhibitor enters next stage of clinical development
Category: News
Company aims to expand treatment options for relapsed or refractory multiple myeloma
Combination therapy moves into late‑stage testing after encouraging earlier results
Company prepares regulatory filings after treatment shows significant reduction in disease flare risk
MRM’s platform could optimise the link between the gut microbiome and cancer outcomes
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
The two companies aim to reduce administrative burden and speed up drug delivery
The blood industry plays a vital role in supporting the development of advanced therapies
Winners will receive metabolomics kits, expert consultation and measurement services
Cell and gene therapies are often delayed by technical and regulatory issues